High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer

Summary. As in most solid tumors, colorectal cancer prognosis strongly depends on the extent of local invasion and lymph node and distant metastases. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a transmembrane glycoprotein that activates matrix metalloproteinases, a group of enzymes...

Full description

Saved in:
Bibliographic Details
Main Authors: Stenzinger, Albrecht (Author) , Goeppert, Benjamin (Author) , Weichert, Wilko (Author)
Format: Article (Journal)
Language:English
Published: 12 March 2012
In: Human pathology
Year: 2012, Volume: 43, Issue: 9, Pages: 1471-1481
ISSN:1532-8392
DOI:10.1016/j.humpath.2011.10.023
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/j.humpath.2011.10.023
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0046817711004746
Get full text
Author Notes:Albrecht Stenzinger MD, Daniel Wittschieber MD, Moritz von Winterfeld MD, Benjamin Goeppert MD, Carsten Kamphues MD, Wilko Weichert MD, Manfred Dietel MD, Anja Rabien PhD, Frederick Klauschen MD
Description
Summary:Summary. As in most solid tumors, colorectal cancer prognosis strongly depends on the extent of local invasion and lymph node and distant metastases. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a transmembrane glycoprotein that activates matrix metalloproteinases, a group of enzymes that play an important role in tumor invasion and metastasis formation. This study investigates the EMMPRIN expression in a large cohort of patients with colorectal cancer. Immunohistochemical analysis of tissue microarrays from 285 patients shows that increased EMMPRIN protein expression does not correlate with clinicopathologic parameters and is an independent prognostic factor of poor survival, with mean survival times of 103 months in EMMPRIN negative/low versus 57 months in EMMPRIN intermediate/high patients (P < .001). This pronounced association of increased EMMPRIN levels and—on average—a 45% reduction in overall survival could help improve the risk stratification in patients with colorectal cancer; moreover, the lack of correlations with classical measures of cancer invasion/spreading may suggest the relevance of alternative EMMPRIN pathways beyond matrix metalloproteinase activation.
Item Description:Gesehen am 02.09.2020
Physical Description:Online Resource
ISSN:1532-8392
DOI:10.1016/j.humpath.2011.10.023